Ингибитор дипептидилпептидазы-IV - ситаглиптин: новые возможности терапии сахарного диабета 2 типа

Полный текст:

Об авторе

T I Romantsova

Список литературы

1. Aschner P, Kipnes M, Lunceford J. et al. Sitagliptin monotherapy improved glycemic control in the fasting and postprandial states and beta-cell function after 24 weeks in patients with type 2 diabetes (T2DM) [abstract]. Presented at:American Diabetes Association 66th Annual Scientific Sessions;June 9-13 2006;Washington, DC. Abstract 1995-PO.

2. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. J Clin Pract. 2006, 60, 11, 1454-1470.

3. Barragan JM, Eng J, Rodriguez R, Blazquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol. 1999;277:E784-E791.

4. Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor:a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28:55-72.

5. Brazg R, Thomas K, Zhao P et al. Effect of adding MK-0431 to on-going metformin therapy in type 2 diabetic patients who have inadequate glycemic control on metformin [abstract]. Presented at:American Diabetes Association 65th Annual Scientific Sessions;June 10-14, 2005;San Diego, Calif. Abstract 11-OR.

6. Brown JC, Pederson RA. GI hormones and insulin secretion. In:James VHT (ed) 5th International Congress on Endocrinology. 1976;vol 2. Excerpta Medica, Hamburg, pp 568-570.

7. Brown JC. A gastric inhibitory polypeptide. I. The amino acid composition and the tryptic peptides. Can J Biochem. 1971;49:255-261.

8. Creutzfeldt W. The incretin concept today. Diabetologia. 1979;16:75-85.

9. De Leon DD, Deng S, Madani R et al. Role of endogenous glucagon-like peptide-1 in islet regeneration following partial pancreatectomy. Diabetes. 2003;52:365-371.

10. Deacon CF, Ahren B, Holst J. Inhibitors of dipeptidyl peptidase IV:a novel approach for the prevention and treatment of type 2 diabetes? Expert Opin Investig Drugs. 2004;13:1091-1102.

11. Deacon CF, Nauck MA, Toft-Nielsen M et al.:Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44:1126-1131.

12. Drucker DJ The evidence for ahieving glycemic control with incretin mimetics.The Diabetes Educator, Vol. 32, No Supplement 2, 72S-81S, 2006.

13. Drucker DJ, Philippe J, Mojsov S et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA. 1987;84:3434-3438.

14. Drucker DJ. Glucagon like peptides. Diabetes, 1998;47:159-169.

15. Drucker DJ. Minireview:the glucagon-like peptides. Endocrinology. 2001;142:521-527.

16. Drucker DJ. Incretine-based therapies. A clinical need filled by unique metabolic effects. The Diabetes Educator. 2006;Vol. 32, No Supplement 2, 65S-71S

17. Dungan K, Buse JB. Glucagon-like peptide 1-based therapies for type 2 diabetes:a focus on exenatide. Clin Diabetes, 2005;23:56-62.

18. Elrick H, Stimmler L, Hlad CJ, Arai Y. Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076-1082.

19. Eng J, Kleinman WA, Singh L et al. Isolation and characterization of exendin 4, an exendin 3 analogue from Heloderma suspectum venom. J Biol Chem. 1992, 267:7402-7405.

20. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101:515-520.

21. Gromada J, Bokvist K, Ding WG et al. Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes. 1998;47:57-65.

22. Gromada J, Dissing S, Bokvist K et al. Glucagon-like peptide I increases cytoplasmic calcium in insulin- secreting beta TC3-cells by enhancement of intracellular calcium mobilization. Diabetes. 1995;44:767-774.

23. Habener JF. The incretin notion and its relevance to diabetes. In:Vinik AI (ed) Gastrointestinal Hormones in Medicine. WB Saunders Company, Philadelphia. 1993;vol 22:775-794.

24. Hargrove DM, Nardone NA, Persson LM et al. Glucose-dependent action of glucagon-like peptide-1(7-37) in vivo during short- or long-term administration. Metabolism. 1995;44:1231-1237.

25. Heine RJ, Van Gaal LF, Johns D, et al. GWAA Study Group:Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes:a randomized trial. Ann Intern Med. 2005, 143:559-569.

26. Herman GA, Bergman A, Fang L, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of MK-0431 over 28 days in middle-aged, obese subjects [abstract]. Presented at:American Diabetes Association 65th Annual Scientific Sessions;June 10-14, 2005;San Diego, Calif. Abstract 497-P.

27. Holz GG, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature. 1993;361:362-365.

28. Hui H, Wright C, Perfetti R. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes. 2001;50:785-796.

29. Imeryuz N, Yegen BC, Bozkurt A et al. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol. 1997;273:G920-G927.

30. Karasik A, Charbonnel B, Liu J, et al. Sitaglipitin added to ongoing metformin therapy enhanced glycemic control and beta-cell function in patients with type 2 diabetes. Presented at:American Diabetes Association 66th Annual Scientific Sessions; June 9-13, 2006; Washington, DC. Abstract 501-P.

31. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20:876-913.

32. List JF, Habener JF. Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells. Am J Physiol Endocrinol Metab. 2004;286:E875-E881.

33. Meier J, Gallwitz B, Schmidt W, Nauck M. Glucagon-like peptide 1 as a regulator of food intake and body weight:therapeutic perspectives. Eur J Pharmacol. 2002;440:269-270.

34. Moore B, Edie ES, Abram JH. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochem J. 1906;1:28-38.

35. Nauck MA, Heimesaat MM, Behle K et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87:1239-1246.

36. Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63:492-498.

37. Nauck MA, Sauerwald A, Ritzel R et al. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care. 1998;21:1925-1931.

38. Orskov C, Holst JJ, Poulsen SS, Kirkegaard P Pancreatic and intestinal processing of proglucagon in man. Diabetelogia. 1987;30:874-881.

39. Perfetti R, Merkel P. Glucagon-like peptide-1:a major regulator of pancreatic-cell function. Eur J Endocrinol. 2000;143:717-725.

40. Ritzel R, Schulte M, Porksen N, Nauck MS, et al. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance. Diabetes. 2001;50:776-784.

41. Rosenstock J, Brazg R, Andryuk PJ, et al. Addition of sitagliptin to pioglitazone improved glycemic control with neutral weight effect over 24 weeks in inadequately controlled type 2 diabetes (T2DM) [abstract]. Presented at:American Diabetes Association 66th Annual Scientific Sessions;June 9-13, 2006; Washington, DC. Abstract 556-P.

42. Schick R.R., Zimmermann J.P., vorm Walde T. et al. Peptides that regulate food intake:glucagon-like peptide 1-(7-36) amide at lateral and medial hypothalamic sites to suppress feeding in rats. Am J Physiol. 2003;284:R1427-R1435.

43. Schirra J, Wank U, Arnold R, Goke B, Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans. Gut. 2002;50:341-348.

44. Scrocchi LA, Brown TJ, MaClusky N, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med. 1996;2:1254-1258.

45. Turton DD, O'Shea D, Gunn J et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379:69-72.

46. Vilsboll T, Krarup T, Deacon CF et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609-613.

47. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept. 2003, 114:115-121.

48. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both_cell replication and neogenesis, resulting in increased - cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270-2276.

49. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagonlike peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes:a parallel-group study. Lancet. 2002;359:824-830.

50. Zunz E, LaBarre J . Contributions a l'etude des variations physiologiques de la secretion interne du pancreas:realations entre les secretions externe et interne du pancreas. Arch Int Physiol Biochim, 1929.

Для цитирования:

Romantsova T.I. Ингибитор дипептидилпептидазы-IV - ситаглиптин: новые возможности терапии сахарного диабета 2 типа. Ожирение и метаболизм. 2006;3(4):22-28.

For citation:

. Ingibitor dipeptidilpeptidazy-IV - sitagliptin: novye vozmozhnosti terapii sakharnogo diabeta 2 tipa. Obesity and metabolism. 2006;3(4):22-28. (In Russ.)

Просмотров: 7

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)